Vitreomacular interface abnormalities in patients with diabetic macular oedema and their implications on the response to anti-VEGF therapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1435-702X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Vitreomacular interface abnormalities in patients with diabetic macular oedema and their implications on the response to anti-VEGF therapy ; volume:256 ; number:8 ; day:19 ; month:5 ; year:2018 ; pages:1411-1418 ; date:8.2018
Graefe's archive for clinical and experimental ophthalmology ; 256, Heft 8 (19.5.2018), 1411-1418, 8.2018
- Creator
-
Mikhail, Michael
- Contributor
-
Stewart, Stephen
Seow, Felicia
Hogg, Ruth
Lois, Noemi
SpringerLink (Online service)
- DOI
-
10.1007/s00417-018-4009-6
- URN
-
urn:nbn:de:101:1-2018091920321268893317
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:27 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mikhail, Michael
- Stewart, Stephen
- Seow, Felicia
- Hogg, Ruth
- Lois, Noemi
- SpringerLink (Online service)
Other Objects (12)
The impact of Vitreo-Macular interface abnormalities on the response to Anti-VEGF therapy for centre involving diabetic macular oedema
Efficacy of anti-VEGF monotherapy versus anti-VEGF therapy with subthreshold micropulse laser (SML) in the management of diabetic macular oedema (DMO): a systematic review and meta-analysis
Anti-VEGF for the management of diabetic macular edema
Vitreomacular interface after anti-VEGF injections in diabetic macular edema
Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema
Anti-VEGF : 13 tables
Repeated Dexamethasone Intravitreal Implant for the Treatment of Diabetic Macular Oedema Unresponsive to Anti-VEGF Therapy: Outcome and Predictive SD-OCT Features
Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema
Psychological impact of anti-VEGF treatments for wet macular degeneration—a review
Fibrosis in age-related neovascular macular degeneration in the anti-VEGF era
Real-World Outcomes of Anti-VEGF Therapy in Diabetic Macular Oedema: Barriers to Treatment Success and Implications for Low/Lower-Middle-Income Countries
Development of Macular Atrophy in Patients with Wet Age-Related Macular Degeneration Receiving Anti-VEGF Treatment
The impact of Vitreo-Macular interface abnormalities on the response to Anti-VEGF therapy for centre involving diabetic macular oedema
Efficacy of anti-VEGF monotherapy versus anti-VEGF therapy with subthreshold micropulse laser (SML) in the management of diabetic macular oedema (DMO): a systematic review and meta-analysis
Anti-VEGF for the management of diabetic macular edema
Vitreomacular interface after anti-VEGF injections in diabetic macular edema
Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema
Anti-VEGF : 13 tables
Repeated Dexamethasone Intravitreal Implant for the Treatment of Diabetic Macular Oedema Unresponsive to Anti-VEGF Therapy: Outcome and Predictive SD-OCT Features
Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema
Psychological impact of anti-VEGF treatments for wet macular degeneration—a review
Fibrosis in age-related neovascular macular degeneration in the anti-VEGF era
Real-World Outcomes of Anti-VEGF Therapy in Diabetic Macular Oedema: Barriers to Treatment Success and Implications for Low/Lower-Middle-Income Countries
Development of Macular Atrophy in Patients with Wet Age-Related Macular Degeneration Receiving Anti-VEGF Treatment
The impact of Vitreo-Macular interface abnormalities on the response to Anti-VEGF therapy for centre involving diabetic macular oedema
Efficacy of anti-VEGF monotherapy versus anti-VEGF therapy with subthreshold micropulse laser (SML) in the management of diabetic macular oedema (DMO): a systematic review and meta-analysis
Anti-VEGF for the management of diabetic macular edema
Vitreomacular interface after anti-VEGF injections in diabetic macular edema
Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema
Anti-VEGF : 13 tables
Repeated Dexamethasone Intravitreal Implant for the Treatment of Diabetic Macular Oedema Unresponsive to Anti-VEGF Therapy: Outcome and Predictive SD-OCT Features
Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema
Psychological impact of anti-VEGF treatments for wet macular degeneration—a review
Fibrosis in age-related neovascular macular degeneration in the anti-VEGF era
Real-World Outcomes of Anti-VEGF Therapy in Diabetic Macular Oedema: Barriers to Treatment Success and Implications for Low/Lower-Middle-Income Countries